{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:36:58Z","timestamp":1790699818102,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T00:00:00Z","timestamp":1503273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T00:00:00Z","timestamp":1503273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatic fibrosis is the net accumulation of matrix tissue components which controlled by pro-fibrolytic enzymes, matrix metalloproteinases (MMPs), and pro-fibrotic cytokine, TGF-\u03b2<jats:sub>1<\/jats:sub>, and enzymes, tissue inhibitors of MMPs (TIMPs). Vitamin D (VD) supplementation has been shown to reverse these processes <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. This study sought to determine the effect of VD supplementation on serum fibrotic markers in chronic hepatitis C (CHC) patients. Fifty-four CHC patients with VD deficiency were randomized into two groups, a VD group (n\u2009=\u200929) and a placebo group (n\u2009=\u200929). The serum levels of 25-hydroxy VD, TGF-\u03b2<jats:sub>1<\/jats:sub>, TIMP-1, MMP2 and MMP9 were measured at baseline and at the end of the 6-week study period. Upon correction of VD levels, TGF-\u03b2<jats:sub>1<\/jats:sub> and TIMP-1 levels were decreased, and the MMP2 and MMP9 levels were significantly increased in the VD group. A comparison of the mean changes (delta) in the markers between groups showed that TGF-\u03b2<jats:sub>1<\/jats:sub> and TIMP-1 levels were significantly decreased and the MMP2 and MMP9 were significantly higher in the VD group than in the placebo group. By using CHC patients as a model, this study provides additional evidence that VD plays an important role in the reversal of hepatic fibrogenesis.<\/jats:p>","DOI":"10.1038\/s41598-017-09512-7","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T09:48:51Z","timestamp":1502790531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: A randomized, double-blind, placebo-controlled study"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-9547","authenticated-orcid":false,"given":"Piyawat","family":"Komolmit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayamon","family":"Kimtrakool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirinporn","family":"Suksawatamnuay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kessarin","family":"Thanapirom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanita","family":"Chattrasophon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panarat","family":"Thaimai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintana","family":"Chirathaworn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"key":"9512_CR1","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","volume":"64","author":"YA Lee","year":"2015","unstructured":"Lee, Y. A., Wallace, M. C. & Friedman, S. L. Pathobiology of liver fibrosis: a translational success story. Gut \n                           64, 830\u2013841, doi:10.1136\/gutjnl-2014-306842 (2015).","journal-title":"Gut"},{"key":"9512_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1172\/JCI31487","volume":"117","author":"TA Wynn","year":"2007","unstructured":"Wynn, T. A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. The Journal of clinical investigation \n                           117, 524\u2013529, doi:10.1172\/jci31487 (2007).","journal-title":"The Journal of clinical investigation"},{"key":"9512_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet (London, England) \n                           388, 1081\u20131088, doi:10.1016\/s0140-6736(16)30579-7 (2016).","journal-title":"Lancet (London, England)"},{"key":"9512_CR4","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1007\/s10620-009-1069-9","volume":"55","author":"J Arteh","year":"2010","unstructured":"Arteh, J., Narra, S. & Nair, S. Prevalence of vitamin D deficiency in chronic liver disease. Digestive diseases and sciences \n                           55, 2624\u20132628, doi:10.1007\/s10620-009-1069-9 (2010).","journal-title":"Digestive diseases and sciences"},{"key":"9512_CR5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3748\/wjg.v17.i7.922","volume":"17","author":"M Malham","year":"2011","unstructured":"Malham, M. et al. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World journal of gastroenterology: WJG \n                           17, 922\u2013925, doi:10.3748\/wjg.v17.i7.922 (2011).","journal-title":"World journal of gastroenterology: WJG"},{"key":"9512_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/lt.23646","volume":"19","author":"M Venu","year":"2013","unstructured":"Venu, M., Martin, E., Saeian, K. & Gawrieh, S. High prevalence of vitamin A deficiency and vitamin D deficiency in patients evaluated for liver transplantation. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society \n                           19, 627\u2013633, doi:10.1002\/lt.23646 (2013).","journal-title":"Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society"},{"key":"9512_CR7","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/hep.23489","volume":"51","author":"S Petta","year":"2010","unstructured":"Petta, S. et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology (Baltimore, Md.) \n                           51, 1158\u20131167, doi:10.1002\/hep.23489 (2010).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"9512_CR8","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jhep.2010.08.036","volume":"54","author":"CM Lange","year":"2011","unstructured":"Lange, C. M. et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. Journal of hepatology \n                           54, 887\u2013893, doi:10.1016\/j.jhep.2010.08.036 (2011).","journal-title":"Journal of hepatology"},{"key":"9512_CR9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/hep.27281","volume":"60","author":"M Garcia-Alvarez","year":"2014","unstructured":"Garcia-Alvarez, M. et al. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis. Hepatology (Baltimore, Md.) \n                           60, 1541\u20131550, doi:10.1002\/hep.27281 (2014).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"9512_CR10","doi-asserted-by":"publisher","first-page":"818","DOI":"10.5009\/gnl15331","volume":"10","author":"BJ Ko","year":"2016","unstructured":"Ko, B. J. et al. Relationship between 25-Hydroxyvitamin D Levels and Liver Fibrosis as Assessed by Transient Elastography in Patients with Chronic Liver Disease. Gut and liver \n                           10, 818\u2013825, doi:10.5009\/gnl15331 (2016).","journal-title":"Gut and liver"},{"key":"9512_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick, M. F. Vitamin D deficiency. The New England journal of medicine \n                           357, 266\u2013281, doi:10.1056\/NEJMra070553 (2007).","journal-title":"The New England journal of medicine"},{"key":"9512_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/gutjnl-2014-307024","volume":"64","author":"A Beilfuss","year":"2015","unstructured":"Beilfuss, A. et al. Vitamin D counteracts fibrogenic TGF-beta signalling in human hepatic stellate cells both receptor-dependently and independently. Gut \n                           64, 791\u2013799, doi:10.1136\/gutjnl-2014-307024 (2015).","journal-title":"Gut"},{"key":"9512_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cell.2013.03.028","volume":"153","author":"N Ding","year":"2013","unstructured":"Ding, N. et al. A vitamin D receptor\/SMAD genomic circuit gates hepatic fibrotic response. Cell \n                           153, 601\u2013613, doi:10.1016\/j.cell.2013.03.028 (2013).","journal-title":"Cell"},{"key":"9512_CR14","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/hep.25830","volume":"56","author":"F Grunhage","year":"2012","unstructured":"Grunhage, F. et al. Common genetic variation in vitamin D metabolism is associated with liver stiffness. Hepatology (Baltimore, Md.) \n                           56, 1883\u20131891, doi:10.1002\/hep.25830 (2012).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"9512_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1478-3231.2011.02674.x","volume":"32","author":"K Baur","year":"2012","unstructured":"Baur, K. et al. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver international: official journal of the International Association for the Study of the Liver \n                           32, 635\u2013643, doi:10.1111\/j.1478-3231.2011.02674.x (2012).","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"key":"9512_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ejphar.2016.07.052","volume":"789","author":"E Wahsh","year":"2016","unstructured":"Wahsh, E., Abu-Elsaad, N., El-Karef, A. & Ibrahim, T. The vitamin D receptor agonist, calcipotriol, modulates fibrogenic pathways mitigating liver fibrosis in-vivo: An experimental study. European journal of pharmacology \n                           789, 362\u2013369, doi:10.1016\/j.ejphar.2016.07.052 (2016).","journal-title":"European journal of pharmacology"},{"key":"9512_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3851\/IMP2264","volume":"18","author":"D El-Maouche","year":"2013","unstructured":"El-Maouche, D. et al. Vitamin D deficiency and its relation to bone mineral density and liver fibrosis in HIV-HCV coinfection. Antiviral therapy \n                           18, 237\u2013242, doi:10.3851\/imp2264 (2013).","journal-title":"Antiviral therapy"},{"key":"9512_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jhep.2012.11.017","volume":"58","author":"MT Kitson","year":"2013","unstructured":"Kitson, M. T. et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of hepatology \n                           58, 467\u2013472, doi:10.1016\/j.jhep.2012.11.017 (2013).","journal-title":"Journal of hepatology"},{"key":"9512_CR19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/gutjnl-2014-308175","volume":"64","author":"V Nobili","year":"2015","unstructured":"Nobili, V. & Reif, S. Vitamin D and liver fibrosis: let\u2019s start soon before it\u2019s too late. Gut \n                           64, 698\u2013699, doi:10.1136\/gutjnl-2014-308175 (2015).","journal-title":"Gut"},{"key":"9512_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1159\/000374096","volume":"33","author":"M Pinzani","year":"2015","unstructured":"Pinzani, M. Pathophysiology of Liver Fibrosis. Digestive diseases (Basel, Switzerland). \n                           33, 492\u2013497, doi:10.1159\/000374096 (2015).","journal-title":"Digestive diseases (Basel, Switzerland)."},{"key":"9512_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/jvh.12072","volume":"20","author":"S Petta","year":"2013","unstructured":"Petta, S. et al. Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. Journal of viral hepatitis \n                           20, 486\u2013493, doi:10.1111\/jvh.12072 (2013).","journal-title":"Journal of viral hepatitis"},{"key":"9512_CR22","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jhep.2011.01.041","volume":"55","author":"B Terrier","year":"2011","unstructured":"Terrier, B. et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Journal of hepatology \n                           55, 756\u2013761, doi:10.1016\/j.jhep.2011.01.041 (2011).","journal-title":"Journal of hepatology"},{"key":"9512_CR23","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/hep.20092","volume":"39","author":"KD Lindor","year":"2004","unstructured":"Lindor, K. D. et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (Baltimore, Md.) \n                           39, 770\u2013778, doi:10.1002\/hep.20092 (2004).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"9512_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine \n                           362, 1675\u20131685, doi:10.1056\/NEJMoa0907929 (2010).","journal-title":"The New England journal of medicine"},{"key":"9512_CR25","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry, M. P. et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. The New England journal of medicine \n                           373, 2618\u20132628, doi:10.1056\/NEJMoa1512614 (2015).","journal-title":"The New England journal of medicine"},{"key":"9512_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/apt.12273","volume":"37","author":"C Koh","year":"2013","unstructured":"Koh, C. et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Alimentary pharmacology & therapeutics \n                           37, 887\u2013894, doi:10.1111\/apt.12273 (2013).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"9512_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (London, England) \n                           381, 468\u2013475, doi:10.1016\/s0140-6736(12)61425-1 (2013).","journal-title":"Lancet (London, England)"},{"key":"9512_CR28","doi-asserted-by":"publisher","unstructured":"EASL Recommendations on Treatment of Hepatitis C 2016. Journal of hepatology \n                           66, 153\u2013194, doi:10.1016\/j.jhep.2016.09.001 (2017).","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"9512_CR29","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1053\/jhep.2003.50176","volume":"37","author":"M Gascon-Barre","year":"2003","unstructured":"Gascon-Barre, M. et al. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology (Baltimore, Md.) \n                           37, 1034\u20131042, doi:10.1053\/jhep.2003.50176 (2003).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"9512_CR30","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1136\/gut.2010.234666","volume":"60","author":"S Abramovitch","year":"2011","unstructured":"Abramovitch, S. et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut \n                           60, 1728\u20131737, doi:10.1136\/gut.2010.234666 (2011).","journal-title":"Gut"},{"key":"9512_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1040-4","volume":"14","author":"AH Abdelghany","year":"2016","unstructured":"Abdelghany, A. H., BaSalamah, M. A., Idris, S., Ahmad, J. & Refaat, B. The fibrolytic potentials of vitamin D and thymoquinone remedial therapies: insights from liver fibrosis established by CCl4 in rats. Journal of translational medicine \n                           14, 281, doi:10.1186\/s12967-016-1040-4 (2016).","journal-title":"Journal of translational medicine"},{"key":"9512_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-8278(99)80001-4","volume":"30","author":"H Tsushima","year":"1999","unstructured":"Tsushima, H. et al. Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. Journal of hepatology \n                           30, 1\u20137 (1999).","journal-title":"Journal of hepatology"},{"key":"9512_CR33","doi-asserted-by":"publisher","first-page":"E3186","DOI":"10.1073\/pnas.1119964109","volume":"109","author":"P Ramachandran","year":"2012","unstructured":"Ramachandran, P. et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America \n                           109, E3186\u20133195, doi:10.1073\/pnas.1119964109 (2012).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9512_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nri3623","volume":"14","author":"A Pellicoro","year":"2014","unstructured":"Pellicoro, A., Ramachandran, P., Iredale, J. P. & Fallowfield, J. A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nature reviews. Immunology \n                           14, 181\u2013194, doi:10.1038\/nri3623 (2014).","journal-title":"Nature reviews. Immunology"},{"key":"9512_CR35","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1365-2893.2006.00730.x","volume":"13","author":"C Trocme","year":"2006","unstructured":"Trocme, C. et al. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. Journal of viral hepatitis \n                           13, 643\u2013651, doi:10.1111\/j.1365-2893.2006.00730.x (2006).","journal-title":"Journal of viral hepatitis"},{"key":"9512_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1572-0241.2004.04055.x","volume":"99","author":"V Leroy","year":"2004","unstructured":"Leroy, V. et al. Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid. The American journal of gastroenterology \n                           99, 271\u2013279, doi:10.1111\/j.1572-0241.2004.04055.x (2004).","journal-title":"The American journal of gastroenterology"},{"key":"9512_CR37","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/hep.25763","volume":"56","author":"T Matsumura","year":"2012","unstructured":"Matsumura, T. et al. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology (Baltimore, Md.) \n                           56, 1231\u20131239, doi:10.1002\/hep.25763 (2012).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"9512_CR38","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick, M. F. et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism \n                           96, 1911\u20131930, doi:10.1210\/jc.2011-0385 (2011).","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"9512_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869","volume":"340","author":"D Moher","year":"2010","unstructured":"Moher, D. et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical research ed.) \n                           340, c869, doi:10.1136\/bmj.c869 (2010).","journal-title":"BMJ (Clinical research ed.)"},{"key":"9512_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2710.2005.00644.x","volume":"30","author":"B Marek","year":"2005","unstructured":"Marek, B. et al. TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy. Journal of clinical pharmacy and therapeutics \n                           30, 271\u2013277, doi:10.1111\/j.1365-2710.2005.00644.x (2005).","journal-title":"Journal of clinical pharmacy and therapeutics"},{"key":"9512_CR41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0197-2456(98)00037-3","volume":"19","author":"WD Dupont","year":"1998","unstructured":"Dupont, W. D. & Plummer, W. D. Jr. Power and sample size calculations for studies involving linear regression. Controlled clinical trials \n                           19, 589\u2013601 (1998).","journal-title":"Controlled clinical trials"},{"key":"9512_CR42","unstructured":"Cohen, J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn, (Hillsdale, New Jersey: Lawrence Erlbaum Associates, 1988)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09512-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09512-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09512-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:01:44Z","timestamp":1671786104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09512-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,21]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["9512"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-09512-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,21]]},"assertion":[{"value":"17 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8905"}}